	US 11,701,426 B2
	Non-infective nasal symptom management compositions and methods
Jay Richard Ray, II, Conroe, TX (US)
Assigned to CMPD Licensing, LLC, Conroe, TX (US)
Filed by CMPD Licensing, LLC, Conroe, TX (US)
Filed on Oct. 22, 2018, as Appl. No. 16/167,108.
Prior Publication US 2020/0121795 A1, Apr. 23, 2020
Int. Cl. A61K 47/18 (2017.01); A61K 47/10 (2017.01); A61K 31/56 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61P 37/08 (2006.01); A61K 45/06 (2006.01)

CPC A61K 47/18 (2013.01) [A61K 9/0043 (2013.01); A61K 31/56 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61P 37/08 (2018.01); A61K 45/06 (2013.01)]

14 Claims

1. A method of treating anosmia, the method comprising:

formulating a topical composition for topical nasal administration via nebulization or irrigation comprising:

combining a steroid, theophylline, quinine sulfate, and a diluent,

wherein the steroid comprises methylprednisolone and is combined in an amount about 1 mg to about 10 mg per unit dose,

wherein the theophylline is combined in an amount about 15 mg to about 250 mg per unit dose, and

wherein the quinine sulfate is combined in an amount about 50 mg to about 650 mg per unit dose; and

nasally administering to a subject the topical composition by intranasal irrigation or nebulization to treat anosmia.